OnCo
technologiesTechnologyPhase 2

Magnetic nanoparticle hyperthermia

Magnetic nanoparticle hyperthermia injects iron-oxide nanoparticles into a tumour and heats them from outside with an alternating magnetic field.

NanoTherm received European approval for glioblastoma in 2010 and is used at a small number of German centres, usually with radiotherapy. A phase 2 adjuvant glioblastoma study is recruiting in Poland (NCT06271421); the US prostate focal-ablation study (NCT05010759) was terminated. Systemically delivered magnetic hyperthermia, as opposed to direct intratumoural injection, is still preclinical.

Generic schematic · not to scale · placeholder for the devices front
Transducer arrays · 100-300 kHz alternating field · Mitosis disrupted

How it works

Superparamagnetic iron-oxide nanoparticles deposited in the tumour dissipate heat under an alternating magnetic field, reaching 40-45 °C and sensitising cells to radiation and chemotherapy.

Strengths
  • Heat is generated only where particles sit
  • Adds to radiotherapy without extra systemic toxicity
  • Approved precedent in Europe
Limitations
  • Requires direct injection and a specialised field applicator
  • Uneven particle distribution gives uneven heating
  • Very few centres; a troubled commercial history

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"Magnetic nanoparticle hyperthermia" OR ABSTRACT:"Magnetic nanoparticle hyperthermia") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Magnetic nanoparticle hyperthermia, not a curated reading list.

Connected

8top

Pages like this

not linked directly; found by shared links